Company led recall - Nutricia Multiple Products

COMPANY LED RECALL

We have received a Recall from Danone

on Various products

Reason: Danone is recalling specific batches of Aptamil / Cow & Gate infant milk due to the possible presence of cereulide (toxin).

Please can you ensure that your stores quarantine the product listed below.

Further Information

https://www.food.gov.uk/news-alerts/alert/fsa-prin-05-2026

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Pharmacist Support launches 2026 Student Bursary Scheme with continued support from Alliance Healthcare

Pharmacist Support, the profession’s independent charity dedicated to championing the wellbeing of pharmacy students, trainees and pharmacists, is proud to announce the launch of its 2026 Student Bursary Scheme, supported by Cencora Alliance Healthcare.

Now in the third year of this valued partnership, Cencora Alliance Healthcare’s continued support ensures that pharmacy students facing unexpected challenges during their MPharm that have impacted them financially can access vital financial help at a critical point in their studies.

The Student Bursary Scheme will open to applications on 2 February 2026 and close on 20 April 2026. It offers awards of £3,000 or £5,000 to MPharm students entering their final year in September 2026 who have experienced an unexpected challenge that has had both a personal and financial impact since starting their degree.

A scheme with lasting impact

For more than a decade, the Student Bursary Scheme has quietly but powerfully changed lives. Since the scheme began in 2014, and up to 2025, 103 bursaries have been awarded, totalling £332,000, helping students stay on their courses, complete their degrees, and move forward into the profession.

Demand for support continues to grow. In the most recent scheme year, all 28 fully accredited pharmacy schools in GB agreed to take part, with 88 applications received from students across 24 universities—a clear reflection of both the need for, and trust in, the scheme.

Behind every application is a student with a story. One of those students, Sofia*, shared how the bursary became a turning point during an incredibly difficult time in her life:

“I was facing a set of circumstances that would have been impossible to overcome without financial assistance. I am a single mother of 2 babies and I lived on one side of this country and my university was on the other side. I had just gotten divorced and following that, I became homeless and was really struggling financially and even emotionally. I had no idea how I was going to make it work financially. This bursary has relieved so much of the burden that I was carrying alone on my shoulders. I don't know how I would have been able to finish my degree without the bursary and therefore I was facing the very real and heartbreaking possibility of being left without the qualifications I needed to become a pharmacist. As far as the impact it has had, it wouldn't be an exaggeration to say that this bursary has altered the trajectory of my future and of course the futures of my 2 toddlers. They will get to see their mother graduate this summer thanks to this bursary. Isn’t that amazing?”

A partnership built on shared values

Pharmacist Support and Cencora Alliance Healthcare share a commitment to supporting the next generation of pharmacy professionals, not just academically, but as people navigating real-life challenges.

Danielle Hunt, Chief Executive of Pharmacist Support, said:

“Students are the future of our profession, and too many face unexpected hardship that puts their studies, wellbeing, and confidence at risk. This bursary scheme is about more than financial support—it’s about belief, reassurance, and helping students stay the course. We are incredibly grateful to Cencora Alliance Healthcare for standing alongside us for a third year and helping us make this life-changing support possible.”

Marie Evans, Managing Director of Cencora Alliance Healthcare UK, said:

“We are proud to continue our partnership with Pharmacist Support and to support the Student Bursary Scheme for a third year. Pharmacy students are facing increasing pressures, and we believe it’s vital to help remove barriers that could prevent talented individuals from completing their training and entering the profession.”

Applications now open

The 2026 Student Bursary Scheme will be open to students at fully accredited pharmacy schools from 2 February to 20 April 2026. Full details, eligibility criteria, and application guidance can be found at: https://pharmacistsupport.org/i-need-help-managing-my/student-experience/bursary-scheme/ 

Class 2 recall-Baclofen 10mg/5ml Oral Solution

Syri Limited, T/A SyriMed is recalling batches of product as a precautionary measure due to crystallisation observed over time in the oral solution.

MHRA drug alert link:https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-syri-limited-t-slash-a-syrimed-baclofen-10mg-slash-5ml-oral-solution-el-26-a-slash-06?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=ecd84602-31de-4417-ac67-2e894ecffebb&utm_content=immediately

MHRA drug alert date:03/02/26

Further Information

For medical information enquiries please use the following options:

Email: medinfo@syrimed.co.uk, or telephone +44 (0) 330 1359 422.

For stock control enquiries please email syriwholesale@bnsthamelabs.com

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 2 recall-Carmustine 100 mg Powder and Solvent for Concentrate for Solution for Infusion

Accord Healthcare limited is recalling a single batch due to an out of specification test result.

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-accord-healthcare-ltd-carmustine-100-mg-powder-and-solvent-for-concentrate-for-solution-for-infusion-1-vial-100mg-powder-1-vial-of-3-ml-solvent-el-26-a-slash-05?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=bf9bdbd3-2473-4486-b6dd-04d2961a9c3c&utm_content=immediately

MHRA drug alert date: 2/2/26

Further Information

For medical information enquires please contact Accord Medical Information Department on 01271 385257 or email medinfo@accord-healthcare.com.

For stock control enquiries please contact our Customer Services Team on 0800 373573.

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 3 recall-Aspar Ibuprofen tabs 200mg

Aspar Pharmaceuticals Ltd is recalling specific batches distributed in Aspar, Almus and Numark livery. The batches are being recalled as a precautionary measure following findings of foil perforations in some blisters.

Product recall date: 29/01/26

MHRA recall link:Class 3 Medicines Recall: Aspar Pharmaceuticals Ltd, Ibuprofen 200mg Tablets, Ibucalm 200mg tablets, EL(26)A/07 - GOV.UK

MHRA recall date: 04/02/26

Further Information

For all enquiries regarding this product, please call 020 8205 9846 extension 2209 or email adrian.zahra@aspar.co.uk.

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

National Patient Safety Alert: Class 1 Medicines Recall Notification: Recall of Quetiapine Oral Suspension (unlicensed medicine)

Eaststone Limited is initiating a recall of all batches of quetiapine oral suspension products due to a potential risk of overdose, which could have consequences for the safety of patients.

MHRA Drug alert date: 29/01/26

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/national-patient-safety-alert-class-1-medicines-recall-notification-recall-of-quetiapine-oral-suspension-unlicensed-medicine-manufactured-by-eaststone-limited-due-to-a-potential-for-overdosing-natpsa-slash-2026-slash-002-slash-mhr?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=a09ef640-89c2-4758-9ee1-2f562cdba868&utm_content=immediately#download-documents

Eaststone Limited will be contacting customers who have received affected stock directly

Further Information

For more information or stock and, please contact Eaststone Limited on +44(0)800 678 3102 (Select Option 1) or email specials@eaststone.co.uk 

For medical information queries, please contact Eaststone Limited on +44(0)800 678 3102 (Select Option 3) or email umar.ahmed@eaststone.co.uk 

For all other enquires place contact Eaststone Limited +44(0)800 678 3102 (Select Option 3) or email umar.ahmed@eaststone.co.uk 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 4 caution in use-Arixtra solution for injection, pre-filled syringes

Viatris has received reports of brown discolouration and blockage in the needle of pre-filled syringes of Arixtra. This quality defect is related to oxidation of the syringe needle.

MHRA drug alert Date: 28/1/26

MHRA drug alert link: Class 4 Medicines Defect Notification: Viatris Products Ltd, Arixtra solution for injection, pre-filled syringes, EL(26)A/04 - GOV.UK

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please telephone Viatris UK Healthcare Limited Medical Information on +44 (0)1707 853 000 (select option 1) or email info.uk@viatris.com.

For stock control enquiries please contact telephone Customer Services on +44 (0)1707 853 000 (select option 2).

Class 4 caution in use-Ocumont Eye Ointment 1% w/w

Blumont Pharma Limited is reporting to the MHRA regarding the absence of Braille on the outer carton of one batch of Ocumont Eye Ointment 1% w/w (POM). It was identified that the Braille information was inadvertently omitted during the approval and release process.

MHRA drug alert Date: 27/1/26

MHRA drug alert link: Class 4 Medicines Defect Notification: Blumont Pharma Limited, Ocumont Eye Ointment 1% w/w, EL(26)A/03 - GOV.UK

This is a caution in use only we are not accepting stock returns

further information

For all medical information enquiries and information on this product, please email info@blumontpharma.com, or telephone + 44 (0)1476 978 568.

For stock control enquiries please email info@blumontpharma.com, or telephone + 44 (0)1476 978 568.

Class 3 recall- Fingolimod Glenmark 0.5 mg Hard Capsules

CLASS 3 RECALL

PLEASE READ AND CONFIRM THAT YOU HAVE RECEIVED THIS.

We have received a Class 3 Recall from Glenmark Pharmaceuticals Europe Limited on FINGOLIMOD CAP 0.5MG

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-glenmark-pharmaceuticals-europe-limited-fingolimod-glenmark-0-dot-5-mg-hard-capsules-el-26-a-slash-02?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=53be9484-a57c-41df-9fe0-10338d61497b&utm_content=immediately

MHRA ref: DMRC-38142990

Reason: Glenmark Pharmaceuticals Europe Limited is recalling the above batch after stability testing showed out-of-specification results. The batch is being recalled as a precautionary measure following test results that showed a delay in capsule dissolution.

Please can you ensure that your stores quarantine the product listed below.

Further Information

For all medical information enquiries and information on this product, medical_information@glenmarkpharma.com or telephone 0044 8004 580 383

For stock control enquiries please email orders.uk@glenmarkpharma.com

Please return all affected stock to your original supplier for credit. As Alliance Healthcare has not supplied the affected batch, we will not be accepting returns.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 2 recall-Paliperidone PR pre-filled syringe 50, 75, 100 & 150mg

Mercury Pharmaceuticals Ltd is recalling remaining stock of paliperidone pre-filled syringes as a precautionary measure due to Good Manufacturing Practice (GMP) deficiencies cited during a recent inspection at the finished product manufacturing site.

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-mercury-pharmaceuticals-ltd-paliperidone-mercury-pharma-prolonged-release-suspension-for-injection-in-pre-filled-syringes-el-26-a-slash-01?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=e99da014-d03f-4b15-9aee-619b70601394&utm_content=immediately

MHRA drug alert date: 20/01/26

Further Information

For stock enquiries please contact Advanz Pharma Customer Care Services on +44 (0) 208 588 9441 or email customercare@advanzpharma.com

For medical information enquiries please contact Advanz Pharma Medical Information on +44 (0) 208 588 9131 or email medicalinformation@advanzpharma.com

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.